Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (NCT04279847)

🧪 Interventions in This Study

• INCB057643 (DRUG)
• Ruxolitinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (48 Sites)

Showing the first 25 of 48 sites.

• University of Alabama At Birmingham — Birmingham, Alabama
• University of Colorado Cancer Center — Aurora, Colorado
• University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
• Emory University-Winship Cancer Institute — Atlanta, Georgia
• University of Iowa Hospital and Clinics — Iowa City, Iowa
• Washington University School of Medicine — St Louis, Missouri
• Rutgers Cancer Institute of Nj — New Brunswick, New Jersey
• Nyu Langone Health - Long Island Hospital — Mineola, New York
• Nyu Langone Laura and Isaac Perlmutter Cancer Center — New York, New York
• Weill Medical College of Cornell University — New York, New York
• University of North Carolina At Chapel Hill — Chapel Hill, North Carolina
• University of Cincinnati Cancer Institute — Cincinnati, Ohio
• Ohio State University — Columbus, Ohio
• Oregon Health and Science University — Portland, Oregon
• Texas Oncology-Baylor Sammons Cancer Center — Dallas, Texas
• Md Anderson Cancer Center — Houston, Texas
• Oncology Consultants — Houston, Texas
• Huntsman Cancer Institute At University of Utah — Salt Lake City, Utah
• Fred Hutchinson Cancer Center — Seattle, Washington
• Princess Margaret Cancer Center — Toronto, Ontario
• McGill University Jewish General Hospital — Montreal, Quebec
• St Paul'S Hospital — Vancouver,
• Peking Union Medical College Hospital — Beijing,
• Nanfang Hospital_Southern Medical University — Guangzhou,
• The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu) — Hangzhou,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myelofibrosis

• Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis — Calgary, Alberta
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Birmingham, Alabama
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Birmingham, Alabama
• A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis — Pasadena, California
• A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) — Newport Beach, California

Explore by condition: All Myelofibrosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.